SCHEMBL5250342

SCHEMBL5250342

FC(F)(F)c1[c]nc2ccccc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.41
HPGD P15428 3/20 0.41
ALDH1A1 P00352 3/20 0.41
GLA P06280 1/20 0.41
ACHE P22303 1/20 0.41
BACE1 P56817 1/20 0.36
PKM P14618 3/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36
POLB P06746 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
THRB P10828 1/20 0.36
NQO2 P16083 1/20 0.35
KDM4E B2RXH2 5/20 0.33
CYP1A2 P05177 1/20 0.33
SLC22A12 Q96S37 1/20 0.33
PABPC1 P11940 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8916440 0.81 MAPT (0.41) MAPTHPGDALDH1A1GLAACHE
SCHEMBL7085947 0.74 ALDH1A1 (0.36) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL558535 0.74 ALDH1A1 (0.46) MAPTHPGDALDH1A1GLAACHE
SCHEMBL7060124 0.69 ALDH1A1 (0.46) MAPTHPGDALDH1A1GLAACHE
SCHEMBL558480 0.69 ALDH1A1 (0.46) MAPTHPGDALDH1A1GLAACHE
SCHEMBL269884 0.69 ALDH1A1 (0.46) MAPTHPGDALDH1A1GLAACHE
SCHEMBL641339 0.69 ALDH1A1 (0.47) MAPTHPGDALDH1A1GLAACHE
SCHEMBL521935 0.69 NQO2 (0.46) MAPTHPGDALDH1A1GLAACHE
SCHEMBL584784 0.69 ALDH1A1 (0.46) MAPTHPGDALDH1A1GLAACHE
SCHEMBL328898 0.69 ALDH1A1 (0.44) MAPTHPGDALDH1A1GLAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1095043-A1 TRIOXANE DERIVATIVES The Hong Kong University of Science & Technology (HK) 2001-05-02 EP claimed
WO-2000004026-A1 TRIOXANE DERIVATIVES THE HONG KONG UNIVERSITY OF SCIENCE & TECHNOLOGY (CN) 2000-01-27 WO claimed
EP-0974354-A1 Artemisinin derivatives The Hong Kong University of Science & Technology (HK) 2000-01-26 EP claimed
WO-2024111206-A1 ORGANIC ELECTRONIC ELEMENT AND COMPOUND 東ソー株式会社 2024-05-30 WO disclosed
WO-2024105964-A1 ORGANIC ELECTRONIC ELEMENT AND COMPOUND 東ソー株式会社 2024-05-23 WO disclosed
EP-3924341-A1 COMPOUNDS, COMPOSITIONS AND METHODS Denali Therapeutics Inc. (US) 2021-12-22 EP disclosed
WO-2020167994-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2020-08-20 WO disclosed
EP-2675526-B1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2017-02-01 EP disclosed
US-9102688-B2 Sulfonaminoquinoline hepcidin antagonists VIFOR (INTERNATIONAL) AG (CH) 2015-08-11 US disclosed
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2014-12-11 US disclosed
EP-2675526-A1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS Vifor (International) AG (CH) 2013-12-25 EP disclosed
US-6649647-B1 Trioxane derivatives HAYNES RICHARD (CN) 2003-11-18 US disclosed
US-6541466-B2 Such as 1-(N'-(3,5-difluorophenylacetyl)-L-alaninyl)-aminodibenzosuberane; for treatment of Alzheimer's disease ATHENA NEUROSCIENCES, INC. 2003-04-01 US disclosed
US-6486153-B1 Phenylindole derivatives as 5-HT2A receptor ligands MERCK SHARP & DOHME LTD. 2002-11-26 US disclosed
EP-1095043-A1 TRIOXANE DERIVATIVES The Hong Kong University of Science & Technology (HK) 2001-05-02 EP disclosed
WO-2000004026-A1 TRIOXANE DERIVATIVES THE HONG KONG UNIVERSITY OF SCIENCE & TECHNOLOGY (CN) 2000-01-27 WO disclosed
EP-0974354-A1 Artemisinin derivatives The Hong Kong University of Science & Technology (HK) 2000-01-26 EP disclosed
WO-1999011619-A1 PHENYLINDOLE DERIVATIVES AS 5-HT2A RECEPTOR LIGANDS MERCK SHARP & DOHME LIMITED (GB) 1999-03-11 WO disclosed
US-4389403-A HYPOTENSIVE AGENTS BASF AKTIENGESELLSCHAFT (DE) 1983-06-21 US disclosed
EP-0037471-A1 1-Aroyl-2-phenylamino-2-imidazolines, their preparation and their pharmaceutical compositions BASF Aktiengesellschaft (DE) 1981-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 MAPT 4801/4885HPGD 104/4885ALDH1A1 3570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.